2026 Q1 -tulosraportti
Vain PDF
103 päivää sitten
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 20.8. | 2 päivää |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 7.5. | ||
2025 Q4 -tulosraportti 26.2. | ||
2025 Q3 -tulosraportti 22.10.2025 | ||
2025 Q2 -tulosraportti 21.8.2025 | ||
2025 Q1 -tulosraportti 8.5.2025 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·5 t sittenA brand new piece of news from Germany Tilray Medical is a big player throughout the EU, and they have chosen to follow the proverb. If you can't beat them, join them. Tilray Medical has both flowers and oils in their assortment, but they have seen the writing on the wall, and will apparently focus on oil. That can only be to Stanocare's advantage, because they don't have as much money as Tilray medical, and cannot perform the same lobbying. But Stenocare can follow in their wake, and reap what Tilray Medical sows. https://www.globenewswire.com/news-release/2026/08/18/3346700/0/de/tilray-medical-begr%C3%BC%C3%9Ft-die-positiven-entwicklungen-im-deutschen-rechtsrahmen-f%C3%BCr-medizinisches-cannabis-und-setzt-sich-f%C3%BCr-dessen-kontinuierliche-weiterentwicklung-ein.html
·9 t sittenWhat do people here expect for the financial report? Germany's revenue will probably not be relevant As the financial report is from before/just release in Germany The stock is slowly falling and falling, what do you think?One can always hope for a positive surprise regarding Germany, but despite all 3D's hype, I really find it hard to see where it would come from. And conversely, if one reads Blueocean's excellent analysis, one cannot rule out that the financial report shows that fierce competition has taken a toll on the crucial Danish market. And it doesn't take much headwind for cash flow to once again turn its nose the wrong way, and then we have trouble, because stenocare is not exactly standing on a solid financial foundation.- ·12 t sitten · MuokattuStock status The batch with Weeco Astrum 10/10 has still not been released yet. Other brands have the same bottlenecks at customs. I just checked for good measure, and I could see that there were red dots next to several other brands. As soon as I see that the oil is back on the shelves, I will naturally write it here. While we wait for Weeco Astrum 10/10 to be released and for the financial report to be published, whichever comes first, We can turn our attention to France to find out if anything is happening right now that might be interesting for us. Although there isn't as much drama as in Germany, I believe that some highly interesting decisions have been made that will benefit Astrum 10/10 (that's what the oil is called in France) I found an article describing how they are preparing to release medical cannabis. Here we can see that they have looked towards Germany and learned from the experiences that German politicians have made. For this reason, only oils and extracts will be released initially, and standardized oils, in particular, are welcomed. Based on the above, we can expect that Astrum 10/10 (as well as Stenocare having found a distributor according to Stenocare's press release) Stenocare's application will be at the top of the pile when things really get going. The article is from August 13. France focuses on extracts, not cannabis flower and vaporizers. https://www.cansativa.de/en/2026/08/13/medical-cannabis-in-france-what-comes-after-the-pilot-programme/
Now you are actually close to the core of the matter. Germany is probably not our big golden egg, at least not yet, but France was mentioned at the general meeting and is indirectly connected to Germany, as Stenocare had been "discovered" by interested parties in France, who saw Stenocare's product in Germany. Germany borders many countries and tourists, and especially students and foreigners working for a longer period, who can potentially "discover" Stenocare's product and take it home and reach out to Stenocare, for eventual distribution, as we are currently seeing with France. But there is some legislation that needs to be in place first, and neither shareholders nor Stenocare have influence over that. It will be exciting to see on Thursday what the financial report and notes show. And just a quick question, how can you see that Stenocare has goods in customs waiting to clear? (Question asked with a desire to gain experience and become wiser). - ·1 päivä sittenFinally, I have found statistics on how much cannabis oil has been sold in Germany and how much is expected to be sold in the future based on the current conditions in Germany. Until now, I have only been able to find statistics where both flowers, oil, and extracts were in the same category. But this one is specifically for oils and extracts; here you can read that the oil segment is the largest and fastest-growing segment in Germany. They expect a growth rate of approx. 26% per year up to and including 2030 You need to scroll down and then you can read that Grand view Horizon provides ongoing updates, which is why there is no date on it, https://www.grandviewresearch.com/horizon/outlook/cannabis-extract-market/germany
- ·2 päivää sittenWhile we wait for Weeco Astrum 10/10 to be released by German customs, I check every day whether the various pharmacies have restocked their shelves with Weeco Astrum 10/10, so I can put the yellow bar on, but we are not there yet. However, a pharmacy in Bonn has received the oil in stock again, by buying internally. Everything below I have deduced based on the research I have conducted since May 13. (It has not been verified by anyone from Stenocare) It's an ill wind that blows nobody any good, because I have wondered why the pharmacies that have permission to do so have bought Weeco Astrum 10/10 internally, after Weeco Pharma's stock has been completely emptied for about 14 days now. I have also noticed that there has been a pharmacy, happyhanf apotek near Fredsege, in Hamburg, which at no point has been sold out. Even though this pharmacy has a large storage capacity, they must comply with German regulations regarding medicine stock, and therefore I dug a little into it. I found out that there is an exception to the rule, and that is that Weeco Pharma is allowed to place a satellite warehouse in a pharmacy's back room, if this meets German regulations. Which I guess Weeco Pharma has done. We don't know when they made the above decision, but if it is to make sense, it must have been after July 10 that they made this decision. But that it should be in Hamburg, and not in the Dusseldoft region, I found strange, because we know that doctors have started prescribing Weeco Astrum 10/10 in large numbers, and Hamburg is 400 km away? Due to this great distance from Dusseldorf, I thought there must be a reason for this madness, and therefore I started to dig a little. Based on the knowledge I have acquired about German regulations, I thought that there can only be one reason why they have placed a satellite warehouse there, and that must be because the majority of people in Hamburg traditionally are larger consumers of vapes and smoke medical cannabis than medical oils, and therefore Weeco Pharma has taken a chance and established a satellite warehouse at this pharmacy in Hamburg, so there will be enough oil for the new users who get a prescription Weeco Astrum 10/10. It is a very expensive chance that Weeco Pharma has taken, if it turns out that they have made a mistake, and therefore that must be the reason why they have placed a satellite warehouse in Hamburg. (Just like the pharmacies, Weeco Pharma is subject to the same rules, and they are also not allowed to just buy in and have Weeco Astrum 10/10 in stock; this must also match the prescriptions being issued) When I have deduced the above, it is because, in addition to the premises having to be approved by the authorities, Weeco Pharma is also not allowed to use this as a reserve stock and sell to their other customers from this stock, but the pharmacy is allowed to sell internally to other pharmacies that have permission to do so. This should be a very cumbersome process, and the profit less than when pharmacies sell directly to customers. The latter is actually the reason why I started to wonder, when it is so cumbersome to have a satellite warehouse as described, there must be a carrot big enough for them to take on the difficulties. Logically, it must be because the pharmacies know who they sell to and how much, and therefore traditionally there must have been more users in Hamburg who bought flowers than oil. The pharmacist has full control over this, so when the subsidy for flower medicine was removed, the pharmacist could see the writing on the wall, that some of these customers would get prescriptions for oil, and then it is good to have so much in stock that they can supply these customers, because you don't make money if you don't have the products on the shelves. It is only if there will be extraordinary sales of oils in Hamburg, as the private flower stock runs out, and if there will be media writing about it, that we will find out if what I have deduced is correct, because I cannot see the number of oils they have in stock, only whether it is in stock or sold out.
could you post a link to a single pharmacy showing that it is sold out?
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2026 Q1 -tulosraportti
Vain PDF
103 päivää sitten
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·5 t sittenA brand new piece of news from Germany Tilray Medical is a big player throughout the EU, and they have chosen to follow the proverb. If you can't beat them, join them. Tilray Medical has both flowers and oils in their assortment, but they have seen the writing on the wall, and will apparently focus on oil. That can only be to Stanocare's advantage, because they don't have as much money as Tilray medical, and cannot perform the same lobbying. But Stenocare can follow in their wake, and reap what Tilray Medical sows. https://www.globenewswire.com/news-release/2026/08/18/3346700/0/de/tilray-medical-begr%C3%BC%C3%9Ft-die-positiven-entwicklungen-im-deutschen-rechtsrahmen-f%C3%BCr-medizinisches-cannabis-und-setzt-sich-f%C3%BCr-dessen-kontinuierliche-weiterentwicklung-ein.html
- ·9 t sittenWhat do people here expect for the financial report? Germany's revenue will probably not be relevant As the financial report is from before/just release in Germany The stock is slowly falling and falling, what do you think?One can always hope for a positive surprise regarding Germany, but despite all 3D's hype, I really find it hard to see where it would come from. And conversely, if one reads Blueocean's excellent analysis, one cannot rule out that the financial report shows that fierce competition has taken a toll on the crucial Danish market. And it doesn't take much headwind for cash flow to once again turn its nose the wrong way, and then we have trouble, because stenocare is not exactly standing on a solid financial foundation.
- ·12 t sitten · MuokattuStock status The batch with Weeco Astrum 10/10 has still not been released yet. Other brands have the same bottlenecks at customs. I just checked for good measure, and I could see that there were red dots next to several other brands. As soon as I see that the oil is back on the shelves, I will naturally write it here. While we wait for Weeco Astrum 10/10 to be released and for the financial report to be published, whichever comes first, We can turn our attention to France to find out if anything is happening right now that might be interesting for us. Although there isn't as much drama as in Germany, I believe that some highly interesting decisions have been made that will benefit Astrum 10/10 (that's what the oil is called in France) I found an article describing how they are preparing to release medical cannabis. Here we can see that they have looked towards Germany and learned from the experiences that German politicians have made. For this reason, only oils and extracts will be released initially, and standardized oils, in particular, are welcomed. Based on the above, we can expect that Astrum 10/10 (as well as Stenocare having found a distributor according to Stenocare's press release) Stenocare's application will be at the top of the pile when things really get going. The article is from August 13. France focuses on extracts, not cannabis flower and vaporizers. https://www.cansativa.de/en/2026/08/13/medical-cannabis-in-france-what-comes-after-the-pilot-programme/Now you are actually close to the core of the matter. Germany is probably not our big golden egg, at least not yet, but France was mentioned at the general meeting and is indirectly connected to Germany, as Stenocare had been "discovered" by interested parties in France, who saw Stenocare's product in Germany. Germany borders many countries and tourists, and especially students and foreigners working for a longer period, who can potentially "discover" Stenocare's product and take it home and reach out to Stenocare, for eventual distribution, as we are currently seeing with France. But there is some legislation that needs to be in place first, and neither shareholders nor Stenocare have influence over that. It will be exciting to see on Thursday what the financial report and notes show. And just a quick question, how can you see that Stenocare has goods in customs waiting to clear? (Question asked with a desire to gain experience and become wiser).
- ·1 päivä sittenFinally, I have found statistics on how much cannabis oil has been sold in Germany and how much is expected to be sold in the future based on the current conditions in Germany. Until now, I have only been able to find statistics where both flowers, oil, and extracts were in the same category. But this one is specifically for oils and extracts; here you can read that the oil segment is the largest and fastest-growing segment in Germany. They expect a growth rate of approx. 26% per year up to and including 2030 You need to scroll down and then you can read that Grand view Horizon provides ongoing updates, which is why there is no date on it, https://www.grandviewresearch.com/horizon/outlook/cannabis-extract-market/germany
- ·2 päivää sittenWhile we wait for Weeco Astrum 10/10 to be released by German customs, I check every day whether the various pharmacies have restocked their shelves with Weeco Astrum 10/10, so I can put the yellow bar on, but we are not there yet. However, a pharmacy in Bonn has received the oil in stock again, by buying internally. Everything below I have deduced based on the research I have conducted since May 13. (It has not been verified by anyone from Stenocare) It's an ill wind that blows nobody any good, because I have wondered why the pharmacies that have permission to do so have bought Weeco Astrum 10/10 internally, after Weeco Pharma's stock has been completely emptied for about 14 days now. I have also noticed that there has been a pharmacy, happyhanf apotek near Fredsege, in Hamburg, which at no point has been sold out. Even though this pharmacy has a large storage capacity, they must comply with German regulations regarding medicine stock, and therefore I dug a little into it. I found out that there is an exception to the rule, and that is that Weeco Pharma is allowed to place a satellite warehouse in a pharmacy's back room, if this meets German regulations. Which I guess Weeco Pharma has done. We don't know when they made the above decision, but if it is to make sense, it must have been after July 10 that they made this decision. But that it should be in Hamburg, and not in the Dusseldoft region, I found strange, because we know that doctors have started prescribing Weeco Astrum 10/10 in large numbers, and Hamburg is 400 km away? Due to this great distance from Dusseldorf, I thought there must be a reason for this madness, and therefore I started to dig a little. Based on the knowledge I have acquired about German regulations, I thought that there can only be one reason why they have placed a satellite warehouse there, and that must be because the majority of people in Hamburg traditionally are larger consumers of vapes and smoke medical cannabis than medical oils, and therefore Weeco Pharma has taken a chance and established a satellite warehouse at this pharmacy in Hamburg, so there will be enough oil for the new users who get a prescription Weeco Astrum 10/10. It is a very expensive chance that Weeco Pharma has taken, if it turns out that they have made a mistake, and therefore that must be the reason why they have placed a satellite warehouse in Hamburg. (Just like the pharmacies, Weeco Pharma is subject to the same rules, and they are also not allowed to just buy in and have Weeco Astrum 10/10 in stock; this must also match the prescriptions being issued) When I have deduced the above, it is because, in addition to the premises having to be approved by the authorities, Weeco Pharma is also not allowed to use this as a reserve stock and sell to their other customers from this stock, but the pharmacy is allowed to sell internally to other pharmacies that have permission to do so. This should be a very cumbersome process, and the profit less than when pharmacies sell directly to customers. The latter is actually the reason why I started to wonder, when it is so cumbersome to have a satellite warehouse as described, there must be a carrot big enough for them to take on the difficulties. Logically, it must be because the pharmacies know who they sell to and how much, and therefore traditionally there must have been more users in Hamburg who bought flowers than oil. The pharmacist has full control over this, so when the subsidy for flower medicine was removed, the pharmacist could see the writing on the wall, that some of these customers would get prescriptions for oil, and then it is good to have so much in stock that they can supply these customers, because you don't make money if you don't have the products on the shelves. It is only if there will be extraordinary sales of oils in Hamburg, as the private flower stock runs out, and if there will be media writing about it, that we will find out if what I have deduced is correct, because I cannot see the number of oils they have in stock, only whether it is in stock or sold out.could you post a link to a single pharmacy showing that it is sold out?
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 20.8. | 2 päivää |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 7.5. | ||
2025 Q4 -tulosraportti 26.2. | ||
2025 Q3 -tulosraportti 22.10.2025 | ||
2025 Q2 -tulosraportti 21.8.2025 | ||
2025 Q1 -tulosraportti 8.5.2025 |
2026 Q1 -tulosraportti
Vain PDF
103 päivää sitten
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 20.8. | 2 päivää |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 7.5. | ||
2025 Q4 -tulosraportti 26.2. | ||
2025 Q3 -tulosraportti 22.10.2025 | ||
2025 Q2 -tulosraportti 21.8.2025 | ||
2025 Q1 -tulosraportti 8.5.2025 |
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·5 t sittenA brand new piece of news from Germany Tilray Medical is a big player throughout the EU, and they have chosen to follow the proverb. If you can't beat them, join them. Tilray Medical has both flowers and oils in their assortment, but they have seen the writing on the wall, and will apparently focus on oil. That can only be to Stanocare's advantage, because they don't have as much money as Tilray medical, and cannot perform the same lobbying. But Stenocare can follow in their wake, and reap what Tilray Medical sows. https://www.globenewswire.com/news-release/2026/08/18/3346700/0/de/tilray-medical-begr%C3%BC%C3%9Ft-die-positiven-entwicklungen-im-deutschen-rechtsrahmen-f%C3%BCr-medizinisches-cannabis-und-setzt-sich-f%C3%BCr-dessen-kontinuierliche-weiterentwicklung-ein.html
- ·9 t sittenWhat do people here expect for the financial report? Germany's revenue will probably not be relevant As the financial report is from before/just release in Germany The stock is slowly falling and falling, what do you think?One can always hope for a positive surprise regarding Germany, but despite all 3D's hype, I really find it hard to see where it would come from. And conversely, if one reads Blueocean's excellent analysis, one cannot rule out that the financial report shows that fierce competition has taken a toll on the crucial Danish market. And it doesn't take much headwind for cash flow to once again turn its nose the wrong way, and then we have trouble, because stenocare is not exactly standing on a solid financial foundation.
- ·12 t sitten · MuokattuStock status The batch with Weeco Astrum 10/10 has still not been released yet. Other brands have the same bottlenecks at customs. I just checked for good measure, and I could see that there were red dots next to several other brands. As soon as I see that the oil is back on the shelves, I will naturally write it here. While we wait for Weeco Astrum 10/10 to be released and for the financial report to be published, whichever comes first, We can turn our attention to France to find out if anything is happening right now that might be interesting for us. Although there isn't as much drama as in Germany, I believe that some highly interesting decisions have been made that will benefit Astrum 10/10 (that's what the oil is called in France) I found an article describing how they are preparing to release medical cannabis. Here we can see that they have looked towards Germany and learned from the experiences that German politicians have made. For this reason, only oils and extracts will be released initially, and standardized oils, in particular, are welcomed. Based on the above, we can expect that Astrum 10/10 (as well as Stenocare having found a distributor according to Stenocare's press release) Stenocare's application will be at the top of the pile when things really get going. The article is from August 13. France focuses on extracts, not cannabis flower and vaporizers. https://www.cansativa.de/en/2026/08/13/medical-cannabis-in-france-what-comes-after-the-pilot-programme/Now you are actually close to the core of the matter. Germany is probably not our big golden egg, at least not yet, but France was mentioned at the general meeting and is indirectly connected to Germany, as Stenocare had been "discovered" by interested parties in France, who saw Stenocare's product in Germany. Germany borders many countries and tourists, and especially students and foreigners working for a longer period, who can potentially "discover" Stenocare's product and take it home and reach out to Stenocare, for eventual distribution, as we are currently seeing with France. But there is some legislation that needs to be in place first, and neither shareholders nor Stenocare have influence over that. It will be exciting to see on Thursday what the financial report and notes show. And just a quick question, how can you see that Stenocare has goods in customs waiting to clear? (Question asked with a desire to gain experience and become wiser).
- ·1 päivä sittenFinally, I have found statistics on how much cannabis oil has been sold in Germany and how much is expected to be sold in the future based on the current conditions in Germany. Until now, I have only been able to find statistics where both flowers, oil, and extracts were in the same category. But this one is specifically for oils and extracts; here you can read that the oil segment is the largest and fastest-growing segment in Germany. They expect a growth rate of approx. 26% per year up to and including 2030 You need to scroll down and then you can read that Grand view Horizon provides ongoing updates, which is why there is no date on it, https://www.grandviewresearch.com/horizon/outlook/cannabis-extract-market/germany
- ·2 päivää sittenWhile we wait for Weeco Astrum 10/10 to be released by German customs, I check every day whether the various pharmacies have restocked their shelves with Weeco Astrum 10/10, so I can put the yellow bar on, but we are not there yet. However, a pharmacy in Bonn has received the oil in stock again, by buying internally. Everything below I have deduced based on the research I have conducted since May 13. (It has not been verified by anyone from Stenocare) It's an ill wind that blows nobody any good, because I have wondered why the pharmacies that have permission to do so have bought Weeco Astrum 10/10 internally, after Weeco Pharma's stock has been completely emptied for about 14 days now. I have also noticed that there has been a pharmacy, happyhanf apotek near Fredsege, in Hamburg, which at no point has been sold out. Even though this pharmacy has a large storage capacity, they must comply with German regulations regarding medicine stock, and therefore I dug a little into it. I found out that there is an exception to the rule, and that is that Weeco Pharma is allowed to place a satellite warehouse in a pharmacy's back room, if this meets German regulations. Which I guess Weeco Pharma has done. We don't know when they made the above decision, but if it is to make sense, it must have been after July 10 that they made this decision. But that it should be in Hamburg, and not in the Dusseldoft region, I found strange, because we know that doctors have started prescribing Weeco Astrum 10/10 in large numbers, and Hamburg is 400 km away? Due to this great distance from Dusseldorf, I thought there must be a reason for this madness, and therefore I started to dig a little. Based on the knowledge I have acquired about German regulations, I thought that there can only be one reason why they have placed a satellite warehouse there, and that must be because the majority of people in Hamburg traditionally are larger consumers of vapes and smoke medical cannabis than medical oils, and therefore Weeco Pharma has taken a chance and established a satellite warehouse at this pharmacy in Hamburg, so there will be enough oil for the new users who get a prescription Weeco Astrum 10/10. It is a very expensive chance that Weeco Pharma has taken, if it turns out that they have made a mistake, and therefore that must be the reason why they have placed a satellite warehouse in Hamburg. (Just like the pharmacies, Weeco Pharma is subject to the same rules, and they are also not allowed to just buy in and have Weeco Astrum 10/10 in stock; this must also match the prescriptions being issued) When I have deduced the above, it is because, in addition to the premises having to be approved by the authorities, Weeco Pharma is also not allowed to use this as a reserve stock and sell to their other customers from this stock, but the pharmacy is allowed to sell internally to other pharmacies that have permission to do so. This should be a very cumbersome process, and the profit less than when pharmacies sell directly to customers. The latter is actually the reason why I started to wonder, when it is so cumbersome to have a satellite warehouse as described, there must be a carrot big enough for them to take on the difficulties. Logically, it must be because the pharmacies know who they sell to and how much, and therefore traditionally there must have been more users in Hamburg who bought flowers than oil. The pharmacist has full control over this, so when the subsidy for flower medicine was removed, the pharmacist could see the writing on the wall, that some of these customers would get prescriptions for oil, and then it is good to have so much in stock that they can supply these customers, because you don't make money if you don't have the products on the shelves. It is only if there will be extraordinary sales of oils in Hamburg, as the private flower stock runs out, and if there will be media writing about it, that we will find out if what I have deduced is correct, because I cannot see the number of oils they have in stock, only whether it is in stock or sold out.could you post a link to a single pharmacy showing that it is sold out?
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt